The rise of autologous HCT for autoimmune diseases: what is behind it and what does it mean for the future of treatment? An update on behalf of the EBMT Autoimmune Diseases Working Party

References

• Duarte RF, Labopin M, Bader P, et al. for the European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant. 2019 Apr 5. [Epub ahead of print]. DOI:10.1038/s41409-019-0516-2.
   Google Scholar
• Snowden JA, Badoglio M, Labopin M, et al. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv. 2017;1:2742–2755.
   PubMed Web of Science ®Google Scholar
• Alexander T, Farge D, Badoglio M, et al. Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Hematopoietic stem cell therapy for autoimmune diseases - clinical experience and mechanisms. J Autoimmun. 2018;92:35–46.
   PubMed Web of Science ®Google Scholar
• Kelsey PJ, Oliveira MC, Badoglio M, et al. Haematopoietic stem cell transplantation in autoimmune diseases: From basic science to clinical practice. Curr Res Transl Med. 2016;64:71–82.
   PubMed Web of Science ®Google Scholar
• Snowden JA. Re-booting autoimmunity with autologous HSCT. Blood. 2016;127(1):8–10.
   PubMed Web of Science ®Google Scholar
• Passweg JR, Baldomero H, Bader P, et al. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European society for blood and marrow transplant activity survey report. Bone Marrow Transplant. 2018 Sep;53(9):1139–1148.
   PubMed Web of Science ®Google Scholar
• Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1997 Apr;19(7):643–645.
   PubMed Web of Science ®Google Scholar
• Snowden JA, Saccardi R, Allez M, et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European group for blood and marrow transplantation. Bone Marrow Transplant. 2012;47:770–790.
   PubMed Web of Science ®Google Scholar
• Alexander T, Bondanza A, Muraro PA, et al. SCT for severe autoimmune diseases: consensus guidelines of the European society for blood and marrow transplantation for immune monitoring and biobanking. Bone Marrow Transplant. 2015;50:173–180.
   PubMed Web of Science ®Google Scholar
• Muraro PA, Pasquini M, Atkins HL, et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol. 2017;74(4):459–469.
   PubMed Web of Science ®Google Scholar
• Mancardi GL, Sormani MP, Gualandi F, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology. 2015;84(10):981–988.
   PubMed Web of Science ®Google Scholar
• Das J, Sharrack B, Snowden JA. Autologous haematopoietic stem cell transplantation in multiple sclerosis: a review of current literature and future directions for transplant haematologists and oncologists. Curr Hematol Malig Rep. 2019;14(2):127–135.
   PubMed Web of Science ®Google Scholar
• Burt RK, Balabanov R, Burman J, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA. 2019;321(2):165–174.
   PubMed Web of Science ®Google Scholar
• Muraro P, Martin R, Mancardi G, et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol. 2017;13(7):391–405.
   PubMed Web of Science ®Google Scholar
• Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011;378:498–506.
   PubMed Web of Science ®Google Scholar
• van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311:2490–2498.
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378:35–47.
   PubMed Web of Science ®Google Scholar
• Farge D, Burt RK, Oliveira MC, et al. Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European society for blood and marrow transplantation autoimmune diseases working party and collaborating partners. Bone Marrow Transplant. 2017;52(11):1495–1503.
   PubMed Web of Science ®Google Scholar
• Smith V, Scirè CA, Talarico R, et al. Systemic sclerosis: state of the art on clinical practice guidelines. RMD Open. 2018 Oct 18;4(Suppl 1):e000782. eCollection 2018.
   PubMedGoogle Scholar
• Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–1339.
   PubMed Web of Science ®Google Scholar
• Brierley CK, Castilla-Llorente C, Labopin M, et al. European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP). autologous haematopoietic stem cell transplantation for Crohn’s disease: a retrospective survey of long-term outcomes from the European society for blood and marrow transplantation. J Crohns Colitis. 2018 May 18. DOI:10.1093/ecco-jcc/jjy069.
   PubMed Web of Science ®Google Scholar
• Hawkey CJ, Allez M, Clark MM, et al. Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA. 2015;314:2524–2534.
   PubMed Web of Science ®Google Scholar
• Lindsay JO, Allez M, Clark M, et al. Autologous stem-cell transplantation in treatment-refractory Crohn’s disease: an analysis of pooled data from the ASTIC trial. Lancet Gastroenterol Hepatol. 2017;2:399–406.
   PubMed Web of Science ®Google Scholar
• Pockley G, Lindsay JO, Foulds GA, et al. on behalf of the EBMT Autoimmune Diseases Working Party (ADWP) and the ASTIClite study investigators. immune reconstitution after autologous haematopoietic stem cell transplantation in Crohn’s disease: Current status and future directions. A review on behalf of the EBMT autoimmune diseases working party and the ASTIClite study investigators. Front Immunol. 2018;9:646.
   PubMed Web of Science ®Google Scholar
• Snowden JA, Panes J, Alexander T, et al. Autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn’s disease: a review on behalf of ECCO and EBMT. J Crohns Colitis. 2018;12(4):476–488.
   PubMed Web of Science ®Google Scholar
• Rose NR. Prediction and prevention of autoimmune disease in the 21st century: a review and preview. Am J Epidemiol. 2016;183:403–406.
   PubMed Web of Science ®Google Scholar
• Jessop H, Farge D, Saccardi R, et al. General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): a position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT nurses group, the EBMT patient, family and donor committee and the joint accreditation committee of ISCT and EBMT (JACIE). Bone Marrow Transplant. 2019 Jan 31. DOI:10.1038/s41409-019-0430-7.
   PubMedGoogle Scholar